Even though no correlation was found between HBVr and combined lines of therapies in both univariate and multivariate analysis in this study, PD-1 inhibitor itself, chemotherapy, targeted agent, TACE (35), HAIC (17), and radiotherapy (36) had all been reported to pose a risk of HBVr in cancer patients. This evidence concerns the gene PDCD1 and cancer.